ReviewExperimental brain research2012
Regulation of α-secretase ADAM10 expression and activity.
Review in Experimental brain research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 80 citations in OpenAlex.
- Mapping the scientific research on exercise therapy for Alzheimer's disease: a scientometric study of hotspots and emerging trends.Frontiers in aging neuroscience · 2025Article
- Examination of Akt and GSK3β in BDNF-mediated reductions in BACE1 activity in neuronal cells.Physiological reports · 2024Article
- Pre-analytical sample handling effects on tear fluid protein levels.Scientific reports · 2023Article
- Shifting the balance: soluble ADAM10 as a potential treatment for Alzheimer's disease.Frontiers in aging neuroscience · 2023Article
- ADAM10 plasma levels predict worsening in cognition of older adults: a 3-year follow-up study.Alzheimer's research & therapy · 2021Article
- Neuroprotective Properties of Resveratrol and Its Derivatives-Influence on Potential Mechanisms Leading to the Development of Alzheimer's Disease.International journal of molecular sciences · 2020Article
- Novel Role for Claudin-11 in the Regulation of Osteoblasts via Modulation of ADAM10-Mediated Notch Signaling.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2019Article
- Functions of 'A disintegrin and metalloproteases (ADAMs)' in the mammalian nervous system.Cellular and molecular life sciences : CMLS · 2019Review
- Transcriptional repression of the ectodomain sheddase ADAM10 by TBX2 and potential implication for Alzheimer's disease.Cellular and molecular life sciences : CMLS · 2019Article
- The expression of the nicotinic acetylcholine receptor α3 subunit in the brains of patients with Alzheimer's disease and its effects on α- and γ-secretases and Notch signal transduction in SH-SY5Y cells.International journal of clinical and experimental pathology · 2019Article
- Role of ADAM10 in intestinal crypt homeostasis and tumorigenesis.Biochimica et biophysica acta. Molecular cell research · 2017Review
- Secretases-related miRNAs in Alzheimer's disease: new approach for biomarker discovery.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2017Review
- Not just amyloid: physiological functions of the amyloid precursor protein family.Nature reviews. Neuroscience · 2017Review
- Restoring Soluble Amyloid Precursor Protein α Functions as a Potential Treatment for Alzheimer's Disease.Journal of neuroscience research · 2017Review
- Monoaminergic neuropathology in Alzheimer's disease.Progress in neurobiology · 2017Review
- ADAM10-Initiated Release of Notch Intracellular Domain Regulates Microtubule Stability and Radial Migration of Cortical Neurons.Cerebral cortex (New York, N.Y. : 1991) · 2017Article
- Therapeutic Potential of Secreted Amyloid Precursor Protein APPsα.Frontiers in molecular neuroscience · 2017Review
- Oxidative stress affects processing of amyloid precursor protein in vascular endothelial cells.PloS one · 2017Article
- A Role for Soluble IL-6 Receptor in Osteoarthritis.Journal of functional morphology and kinesiology · 2017Article
- Modulation of BAG3 Expression and Proteasomal Activity by sAPPα Does Not Require Membrane-Tethered Holo-APP.Molecular neurobiology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The amyloid precursor protein (APP) has a pivotal role in pathogenesis of Alzheimer's disease (AD) via its beta- and gamma-secretase-derived cleavage products--the A-beta peptides. An alternative processing pathway provided by the alpha-secretase prevents formation of those toxic peptides and gives rise to the neurotrophic and neuroprotective cleavage product APPs-alpha. The molecular identity of the alpha-secretase has been confirmed recently, and there is consistency about ADAM10 being the most relevant and physiological enzyme of this class. It is not clear to what extent a deficiency in the catalytic activity of ADAM10 contributes to AD pathology and whether a decline occurs in aging humans. Nevertheless, ADAM10 has been suggested as a valuable target for prevention and/or for treatment of Alzheimer's disease. This review focuses on our knowledge about regulation of ADAM10 on different levels of cell physiology, such as transcription and translation, as well as protein-protein interactions and how this especially in the case of transcriptional regulation by retinoic acids might lead to the development of new therapeutic approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.